Search results
Results from the WOW.Com Content Network
Osteoporosis can affect nearly 1 in 3 women and the bone loss is the most rapid within the first 2–3 years after menopause. This can be prevented by menopause hormone therapy or MHT, which is meant to prevent bone loss and the degradation of the bone microarchitecture and is noted to reduce the risk of fractures in bones by 20-30%.
Unlike osteoporosis, osteopenia does not usually cause symptoms, and losing bone density in itself does not cause pain. There is no single cause for osteopenia, although there are several risk factors, including modifiable (behavioral, including dietary and use of certain drugs) and non-modifiable (for instance, loss of bone mass with age).
Osteoporosis, a skeletal disorder characterized by compromised bone strength and increased risk of fractures, is a major concern in bone health, particularly among older adults. [ 2 ] [ 3 ] Maintaining good bone health involves a combination of adequate calcium and vitamin D intake, regular weight-bearing exercise, and avoiding risk factors ...
Low levels of thyroid hormones can lead to symptoms including fatigue, weight gain, cold intolerance, dry, flakey skin, loss of hair and inability to concentrate.
Senile osteoporosis has been recently recognized as a geriatric syndrome with a particular pathophysiology. There are different classification of osteoporosis: primary, in which bone loss is a result of aging and secondary, in which bone loss occurs from various clinical and lifestyle factors. [1]
Thanks to effective and popular new drugs for weight loss and diabetes – an estimated 1 in 8 adults in the US has used Ozempic or a similar GLP-1 medication – demand for procedures to lift and ...
People taking these drugs can achieve a weight loss of up to 15% of their starting weight within a year. GLP-1 agonists mimic the glucagon-like peptide-1 hormone produced in the gastrointestinal ...
Long-term treatment with bisphosphonates produces anti-fracture and bone mineral density effects that persist for 3–5 years after an initial 3–5 years of treatment. [2] The bisphosphonate alendronate reduces the risk of hip, vertebral, and wrist fractures by 35-39%; zoledronate reduces the risk of hip fractures by 38% and of vertebral ...